11.06.2021 Epigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million | Epigenomics AG | News | Nachricht | Mitteilung
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(0)
The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS
TM (sotorasib) from Amgen
KRAS G12C mutation in NSCLC
Test will be available under QIAGEN s Day One Lab Readiness program
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the
therascreen KRAS RGQ PCR Kit (
therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRAS
QIAGEN N.V.: QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Mirati s investigational selective KRAS
G12C inhibitor
Program adds to QIAGEN s strong position in KRAS companion diagnostic testing in NSCLC
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRAS
G12C mutation who may benefit from treatment with
adagrasib, Mirati s investigational, highly selective and potent oral small molecule inhibitor of KRAS
(2)
U.S. authorization gives healthcare professionals access to portable rapid testing device that can monitor immune status in relation to COVID-19
Test based on QIAGEN partner Ellume s proprietary eHub technology and helps ease testing shortfalls by using automation and providing easy-to-read results
eHub digital device can handle eight tests at once, all working independently of each other, can process up to 32 samples per hour, can eventually be used simultaneously with the antigen test
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach